Short answer
Biogen (BIIB) filed its Q3 2026 10-Q quarterly report on Oct 28, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $2.8B (up 10.6% year over year) with net income of −$21M.
Q3 2026 key financials · XBRL
- Revenue
- $2.8B
- +10.6% YoY · +2.5% QoQ
- Net income
- −$21M
- −104.4% YoY · −121.1% QoQ
- EPS (diluted)
- −$0.15
- −104.7% YoY · −122.7% QoQ
Source: XBRL data from the Biogen (BIIB) Q3 2026 10-Q on SEC EDGAR. USD.
Biogen Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $2,804.1M, up from $2,534.7M YoY, with product revenue $2,088.7M vs $1,846.9M
- Net loss $(20.6)M vs $466.5M income YoY, with net margin (0.7)% vs 18.4%
- Best product line SPINRAZA, $460.6M vs $374.0M; worst TECFIDERA, $82.0M vs $168.2M
- Operating cash flow $1,735.2M for nine months vs $1,692.7M; cash $1,303.9M vs $3,008.5M
- Apellis acquisition deployment $5,071.1M, with $2.0B term loan financing and $400.0M revolving-facility drawdown
Risk Factors
- Newly added international-trade risk: Section 232 Proclamation imposed 100% tariffs on certain pharmaceutical imports beginning July 31, 2026
- Most material product risk: TECFIDERA revenue fell 50.3% to $282.4 million after European patent revocation and generic entry
- Regulatory pricing risk: OBBBA implementation guidance remains pending, with most provisions effective in 2027 and 2028
- Operational risk: Apellis integration may delay expected benefits from EMPAVELI and SYFOVRE commercialization
- Financial risk: Cash and marketable securities declined to $1.3 billion while borrowings increased to $7.7 billion following Apellis acquisition
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biogen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.